Health Costs

The MIDTERMS

“...the search for a single top issue through polling questions — whether it’s health costs, or gas prices, or the cost of food — is artificial. People worry about and experience these costs together. There is no top issue, unless that issue is the catchall, ‘cost of living.’” — Drew Altman, KFF Founding President and CEO

Are Health Care Costs THE Top Issue for Voters?

In a new column, Dr. Drew Altman, Founding President and CEO, analyzes the polling on health costs as a voting issue and concludes that there is no one top voting issue. He writes: “I have come to the conclusion that the search for a single top issue through polling questions—whether it’s health costs, or gas prices, or the cost of food—is artificial. People worry about and experience these costs together. There is no top issue, unless that issue is the catchall, “cost of living.”

Health System Tracker

New and noteworthy

How Unaffordable is Health Care and What Can We Do About It?

Event Date:

On Tuesday, July 21, three experts joined Health Wonk Shop series moderator Larry Levitt in an hour-long discussion of health care affordability. During the discussion, panelists considered affordability from a variety of perspectives, including how to define affordability and the question of affordability for whom, how to measure it, and what can be done to address affordability and the underlying cost of health care.

Stay informed.

Stay informed.

Filter

1,401 - 1,410 of 1,603 Results

  • Majorities Across Party Lines Support Investing More Money in Zika Research and Preventing the Virus’ Spread

    News Release

    Democrats More Favorable to ACA in June, Leading to 44% Unfavorable, 42% Favorable Overall Split Majorities of the public say the United States should invest more money in Zika research and in preventing its spread in this country, the latest Kaiser Health Tracking Poll finds. More than seven in 10 people, including majorities of Democrats, Republicans, and independents, say they support investing in Zika research and to prevent its spread. About two thirds of the…

  • Medicaid’s Most Costly Outpatient Drugs

    Issue Brief

    Using Medicaid State Drug Utilization Data, this brief presents the 50 most costly drugs before rebates used by the Medicaid program over the January 2014 through June 2015 period. It then examines reasons why these drugs are so costly; explores case studies on opioids, hepatitis C drugs, and the drug Abilify; and considers policy implications.

  • Urban and Rural Differences in Coronavirus Pandemic Preparedness

    Issue Brief

    The coronavirus outbreak has hit densely populated urban areas of the United States first and hardest. Some health systems have experienced surges of patients, raising concerns that there are not enough hospital beds, staffing, and equipment. The novel coronavirus was slower to spread to rural areas in the U.S., but that appears to be changing, with new outbreaks becoming evident in less densely populated parts of the country. A new issue brief looks at urban-rural…

  • Update on COVID-19 Funding for Hospitals and Other Providers

    Policy Watch

    This blog is an overview of the outstanding questions related to the $100 billion for hospitals and other providers in the CARES Act and whether there will be meaningful protections for the uninsured and people with private coverage who could face surprise bills.

  • Taking Stock of Essential Workers

    Policy Watch

    The COVID-19 outbreak has changed the reality of working life for most of the U.S. workforce, with essential workers at the forefront of performing crucial services for the public in the midst of the pandemic. This post examines who essential workers are and what challenges they are facing in light of coronavirus.

  • Potential Costs of Coronavirus Treatment for People with Employer Coverage

    Issue Brief

    As COVID-19 spreads within the United States, questions have arisen over the potential costs people may face if they become severely ill and need treatment. While many large insurers have agreed to waive copayments and deductibles for COVID-19 tests, people with private insurance who face deductibles could still be on the hook for large treatment costs. A new brief examines the potential cost of COVID-19 treatment to employer health plans and their enrollees by looking…